CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $361,000 | +7.8% | 5,520 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $335,000 | -3.2% | 5,520 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $346,000 | -18.6% | 5,520 | -1.6% | 0.00% | 0.0% |
| Q4 2021 | $425,000 | -33.9% | 5,609 | -2.4% | 0.00% | 0.0% |
| Q3 2021 | $643,000 | -75.7% | 5,749 | -64.8% | 0.00% | -83.3% |
| Q2 2021 | $2,643,000 | -29.6% | 16,324 | -47.0% | 0.01% | -33.3% |
| Q1 2021 | $3,754,000 | +304.1% | 30,805 | +407.5% | 0.01% | +350.0% |
| Q4 2020 | $929,000 | +76.3% | 6,070 | -3.7% | 0.00% | 0.0% |
| Q3 2020 | $527,000 | +154.6% | 6,300 | +28.8% | 0.00% | +100.0% |
| Q1 2020 | $207,000 | -22.5% | 4,890 | +11.4% | 0.00% | 0.0% |
| Q4 2019 | $267,000 | +1060.9% | 4,390 | +1040.3% | 0.00% | – |
| Q2 2018 | $23,000 | -4.2% | 385 | -26.7% | 0.00% | – |
| Q1 2018 | $24,000 | – | 525 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |